About Us
Our Story
Goldenrod Therapeutics is advancing 11h, a novel small-molecule therapeutic invented by Dr. Corey Hopkins, Chair of the Department of Pharmaceutical Sciences and Director of the Center for Drug Design and Innovation at UNMC. Fannin in-licensed 11h in 2020 and subsequently received SBIR Phase I funding to support its initial development in opioid use disorder.
Since that time, 11h has demonstrated activity across multiple disease-relevant models, supporting expansion into a broader range of neurological and neuropsychiatric indications. In 2023, the program received a DoD Exploration–Hypothesis Development Award for Multiple Sclerosis. In 2024, it was awarded SBIR Phase I funding to support development in methamphetamine use disorder.
With growing evidence of therapeutic potential, 11h is now advancing toward IND-enabling studies.
Mission Statement
To address neuroinflammation, the central component in numerous disease states, and promote neuroprotection and a healthy life starting with a healthier brain.
What We Do
Goldenrod Therapeutics is a biotechnology company developing next-generation, brain-penetrant phosphodiesterase 4 (PDE4) inhibitors for serious neurological disorders. The company focuses on overcoming historical tolerability limitations of earlier PDE4 inhibitors while achieving robust central nervous system exposure.
Through disciplined translational development, Goldenrod advances its lead program toward clinical evaluation with the goal of delivering differentiated therapies for patients with significant unmet medical needs.